Novo Nordisk and Heartseed Enter into Agreement to Develop Cell therapy for Heart Failure
By Shikha Kashyap
Pharma Deals Review: Vol 2021 Issue 7 (Table of Contents)
Published: 7 Jul-2021
DOI: 10.3833/pdr.v2021.i7.2625 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
With the focus of developing new treatment solutions for cardiovascular disease, Novo Nordisk entered into a licensing agreement with Heartseed for the latter’s stem cell-based therapy asset, HS-001, for heart failure...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS